Plasma levels of tumour necrosis factor‐α and adiponectin can differentiate patients with psoriatic arthritis from those with psoriasis
- 29 January 2019
- journal article
- letter
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 181 (2) , 379-380
Abstract
Psoriasis (PsO) and psoriatic arthritis (PsA) are inflammatory disorders. Circulating biomarkers of inflammation such as interleukin‐6 (IL‐6), Tumor Necrosis Factor‐α (TNF‐α), and C‐reactive protein (CRP) have been associated with disease severity and progression of PsO and PsA. Adiponectin and leptin are adipose derived cytokines, recognized as key regulator of body weight and metabolism2. Whether circulating levels of these inflammatory and metabolic biomarkers may predict the risk of PsA in psoriasis populations remains unclear.Keywords
Funding Information
- Amgen (Investigator Initiated Grant)
This publication has 7 references indexed in Scilit:
- Adiponectin regulates psoriasiform skin inflammation by suppressing IL-17 production from γδ-T cellsNature Communications, 2015
- Serum adipokines in patients with psoriatic arthritis and psoriasis alone and their correlation with disease activityAnnals of the Rheumatic Diseases, 2013
- Biomarkers in psoriasis and psoriatic arthritisAnnals of the Rheumatic Diseases, 2013
- Adiponectin as an anti-inflammatory factor in the pathogenesis of psoriasis: induction of elevated serum adiponectin levels following therapyBritish Journal of Dermatology, 2010
- Soluble biomarkers differentiate patients with psoriatic arthritis from those with psoriasis without arthritisRheumatology, 2010
- Adiponectin and inflammation: Consensus and controversyJournal of Allergy and Clinical Immunology, 2008
- TNF‐α and adipocyte biologyFEBS Letters, 2007